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Percutaneous Radiofrequency Ablation of
Hepatocellular Carcinomas Adjacent to
the Gallbladder with Internally Cooled
Electrodes: Assessment of Safety and
Therapeutic Efficacy
Objective: The objective of this study was to evaluate the safety and therapeu-
tic efficacy of percutaneous radiofrequency (RF) ablation for the treatment of
hepatocellular carcinomas (HCCs) adjacent to the gallbladder with the use of
internally cooled electrodes.
Materials and Methods: We retrospectively assessed 45 patients with 46
HCCs (mean size, 2.2 cm) adjacent to the gallbladder ( 1.0 cm) treated with RF
ablation using an internally cooled electrode system. An electrode was inserted
into the tumor either parallel (n = 38) or perpendicular (n = 8) to the gallbladder
wall. The safety and therapeutic efficacy of the procedures were assessed with
clinical and imaging follow-up examinations. Follow-up with the use of CT ranged
from four to 45 months (mean, 19 months). The association between variables
(electrode direction, electrode type, tumor size, tumor location, lobar location)
and the presence of a residual tumor or local tumor progression was also ana-
lyzed.
Results: There were no major complications and minor complications were
noted in three patients (7%) including one case of vasovagal syncope and two
cases of bilomas. Wall thickening of the gallbladder adjacent to the RF ablation
zone was noted in 14 patients (41%) as determined on immediate follow-up CT
imaging. Wall thickening showed complete disappearance on subsequent follow-
up CT imaging. The primary technique effectiveness rate was 96% (44/46) based
on one-month follow-up CT imaging. Local tumor progression was noted in six
(14%) of 44 completely ablated tumors during the follow-up period. The direction
of electrode insertion (perpendicular), tumor size ( 3 cm) and tumor location (a
tumor that abutted the gallbladder) were associated with an increased risk of
early incomplete treatment. No variable was significantly associated with local
tumor progression.
Conclusion: Percutaneous RF ablation of HCCs adjacent to the gallbladder
using an internally cooled electrode is a safe and effective treatment. Significant
risk factors that lead to early incomplete treatment include tumor size, tumor loca-
tion and electrode direction.
adiofrequency (RF) ablation has been regarded as a safe and effective
technique for the treatment of hepatocellular carcinomas (HCCs) (1-5).
In recent studies, for small HCCs, it has been reported that the survival
rate after RF ablation was comparable to the survival rate after surgery (6, 7). With
sufficient experience, RF ablation can be performed easily and safely. However, the
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e-mail: rhimhc@skku.edu  Rprocedure might be limited by intrahepatic or extrahepatic
factors. The heat sink effect decreases the extent of
coagulation necrosis in tumors that are close to large
vessels (8). In addition, collateral thermal damage of
adjacent extrahepatic organs can occur when treating
subcapsular tumors. The gallbladder is at risk for potential
thermal damage; complications such as perforation or
cholecystitis can develop after RF ablation (9, 10).
Several studies that have reported on the safety and
efficacy of RF ablation for hepatic tumors adjacent to the
gallbladder are found in the medical literature (11-14).
However, prior studies have used only multi-tined expand-
able electrodes (11, 12) or had a limited study population
(13, 14). Therapeutic failure after RF ablation can appear
as the presence of a residual unablated tumor or local
tumor progression. However, to the best of our
knowledge, no previous study has focused on the risk
factors for therapeutic failure after RF ablation for an HCC
adjacent to the gallbladder. The goal of this study was to
evaluate the safety and therapeutic efficacy of percuta-
neous RF ablation using an internally cooled electrode
system for the treatment of HCCs adjacent to the gallblad-
der and to assess the risk factors for therapeutic failure
after the procedure.
MATERIALS AND METHODS
Patients
From July 2000 to February 2006, 627 patients with
nodular HCCs were treated using RF ablation with an
internally cooled electrode system at our institution. We
reviewed our institutional database for RF ablation cases
and identified 45 patients who had 46 HCCs adjacent to
the gallbladder. All but one patient had one tumor. Two
HCCs that occurred at different times of the study period
in one patient were ablated in two different sessions. The
patient population included 33 men and 12 women (age
range, 35-86 years; mean age, 62.9 years). Twenty-six
patients were not candidates for surgical treatment or had
unresectable lesions; 19 patients had resectable tumors but
refused surgical treatment.
The maximum diameter of the tumors ranged from 0.7
cm to 4.3 cm (mean, 2.2 cm; standard deviation [SD], 0.76
cm) based on planning ultrasound. Twenty-one tumors
(mean diameter, 2.2 cm; range, 1.0-4.3 cm) abutted the
gallbladder and 25 tumors were located within 1 cm
(range, 0.2-1.0 cm; mean distance, 0.6 cm) of the gallblad-
der. Fifteen tumors (mean diameter, 2.2 cm; range, 0.7-4.0
cm) were located within 0.5 cm of the gallbladder and 10
tumors (mean diameter, 2.1 cm; range, 1.1-3.5 cm) were
located within 0.6-1.0 cm of the gallbladder. The distance
between the tumor and the gallbladder was measured as
the shortest distance on an axial image. If the tumor and
gallbladder were not seen on the same image, the distance
was calculated by multiplying the number of sections that
were included between the two entities by the slice
thickness. Thirty-two tumors were located in liver segment
V, 13 tumors were located in liver segment IV, and one
tumor was located in liver segment VIII.
Twelve patients had gallstones in the gallbladder. Ten
patients had gallbladder wall edema related to cirrhosis as
detected on CT scans obtained before RF ablation. These
patients had neither right upper quadrant pain nor
Murphy’s sign. The criteria for RF ablation for an HCC at
our hospital was the following. Criteria included the
presence of a single nodular HCC that was less than 5 cm
in the maximum diameter. Patients could have up to three
multinodular HCCs, with each tumor measuring up to 3
cm in diameter. Patients presented with no portal venous
thrombosis or an extrahepatic metastasis. Patients had
Child-Pugh classification A or B liver cirrhosis. Patients
had a prothrombin time ratio greater than 50% and a
platelet count greater than 70,000/mm
3. Institutional
Review Board approval and patient written informed
consent were obtained routinely prior to performing RF
ablation therapy.
The diagnosis of HCC was based on the results of a
percutaneous biopsy for five tumors and the characteristic
enhancement pattern depicted on contrast-enhanced
multiphase helical CT with or without elevated serum
tumor markers (n = 11;  -fetoprotein level > 200 ng/mL [>
200 μ g/L]) for the remaining 41 tumors. Of the 45 patients,
42 patients had liver cirrhosis due to hepatitis B (n = 30) or
hepatitis C (n = 12) infection. The remaining three patients
had chronic hepatitis C without liver cirrhosis. Among the
42 cirrhotic patients, 30 patients had Child-Pugh class A
cirrhosis and 12 patients had Child-Pugh class B. Twenty
patients had a history of previous treatment with
transcatheter arterial chemoembolization (TACE) (n =13),
RF ablation (n = 1) or both methods (n = 6). One patient
had a history of undergoing a tumorectomy for HCC.
Radiofrequency Ablation Procedure
Between July 2000 to February 2006, the majority of
percutaneous RF ablations at our hospital were performed
using an internally cooled electrode system (Cool-tip RF
ablation system; Valleylab, Boulder, CO). This device
consists of a needle electrode with a tip internally cooled
by chilled saline and a 200-watt generator. For this study,
all RF ablation procedures were performed with the
internally cooled electrode system under real-time
sonographic guidance (HDI 5000 unit, ATL; Philips
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Medical Solutions, Erlangen, Germany). All patients who
underwent percutaneous RF ablation received a 50 mg
intramuscular injection of pethidine hydrochloride
(Pethidine; Samsung Pharmaceutical, Seoul, Korea) before
the procedure and local anesthesia with the use of
lidocaine (Kwang Myung Pharmaceutical, Seoul, Korea). In
addition, additional pethidine hydrochloride (50 mg) was
administered to patients who complained of intolerable
pain during the ablation procedure. During the procedure,
vital signs were monitored continually. Power was applied
from 50 watts and was gradually increased to the
maximum level for one minute if the patient could tolerate
the procedure with stable vital signs. The mean time for
application of RF was 12 minutes (range, 6-15 minutes). In
three cases with large tumors, two overlapping ablations
were performed to cover the entire tumor. We used a 2-cm
single straight electrode in 10 cases, a 3-cm single straight
electrode in 31 cases and a clustered electrode for five
cases (size range of index tumors, 3.0-4.0 cm; mean size,
3.5 cm) according to the size and location of the tumors. In
general, ablation of an additional 0.5-1 cm of the normal
liver parenchyma around the tumor was necessary to
minimize local tumor progression. However, it was
difficult to obtain a sufficient safety margin surrounding
the tumor close to the gallbladder, especially in areas that
abutted the gallbladder. We classified the direction of
electrode insertion into two categories, parallel or perpen-
dicular, based on whether the tip of electrode was inserted
towards the gallbladder wall (perpendicular) or not
(parallel) (Fig. 1). The direction of electrode insertion was
chosen according to the feasibility of electrode path. Eight
tumors were treated with electrodes inserted perpendicu-
larly and 38 tumors were treated with electrodes inserted
parallel. When inserting a needle electrode into the tumor
parallel to the gallbladder wall, maintenance of a distance
of at least 1.0 cm between the center of the active
electrode tip and the gallbladder wall was attempted. In
cases where the needle electrode was placed perpendicular
to the gallbladder wall, a distance of at least 0.5 cm was
maintained between the electrode tip and the gallbladder
wall. The safety distances mentioned above were based on
the results reported by Ng et al. (15). If a sufficient safety
distance from the gallbladder wall could not be obtained,
especially in cases of small-sized tumors, we located the
electrode off center in the tumor. Further details on the
ablation procedures have been reported previously (16,
17).
Follow-Up Imaging
After RF ablation, contrast-enhanced CT examinations
were performed within two hours (n = 31) or contrast-
enhanced sonography was performed one day after the
procedure (n = 12) or both types of examinations were
performed (n = 3) to assess the completeness of the
ablation and to detect the presence of immediate complica-
tions. Contrast-enhanced sonography was performed after
injection of a microbubble contrast agent (Levovist;
Schering, Berlin, Germany) in 15 patients according to the
preference of the radiologists. Contrast-enhanced CT
examinations were performed with helical scanners
(HiSpeed Advantage or LightSpeed QX/I, GE Healthcare,
Milwaukee, WI).
All patients underwent follow-up with contrast-enhanced
Kim et al.
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Fig. 1. Direction of electrode insertion
(long arrows). It was categorized as
parallel (A) or perpendicular (B) accord-
ing to direction of electrode tip for
gallbladder wall. Distance indicates
safety distance between electrode and
gallbladder wall.
ABthree-phase CT at one-month and then every two to four
months after the ablation. Follow-up with CT ranged from
four to 45 months (mean follow-up, 19 months). Eight
patients died within one year (mean time of death, six
months) due to disease progression, regardless of the
procedure, and seven patients underwent follow-up for less
than 12 months; two patients with residual unablated
tumors received additional TACE and five patients
developed local tumor progression within 12 months after
RF ablation. The 31 remaining patients underwent follow-
up for at least 12 months ( 12 months, n = 18;  24
months, n = 10;  36 months, n = 3). Immediate complica-
tions were assessed by the use of contrast-enhanced
sonography or an immediate follow-up CT scan. However,
evaluation of therapeutic efficacy of RF ablation was
performed at the one-month follow-up with a CT scan. If
any residual unablated tumor or local tumor progression
was noted on follow-up CT, additional therapeutic
procedures such as RF ablation or TACE were attempted.
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Fig. 2. Imaging findings for 69-year-old woman with residual unablated tumor after radiofrequency ablation where vasovagal syncope
occurred during procedure. Electrode was inserted into tumor perpendicular to gallbladder wall. 
A. Contrast-enhanced CT scan obtained during arterial phase shows 1.5-cm hepatocellular carcinoma (arrow) abutting gallbladder
(double arrows) in liver segment IV. 
B. Sagittal sonogram obtained during radiofrequency ablation shows slightly hyperechoic mass (double arrows). Also, note 2-cm active
tip (arrow) of electrode between electronic calipers. 
C. Contrast-enhanced CT scan obtained immediately after radiofrequency ablation shows residual unablated tumor (arrow) seen as
crescent-shape enhancing lesion located at deep portion of ablation zone. 
D. Non-enhanced CT scan obtained after transcatheter arterial chemoembolization shows Lipiodol uptake (arrow) by residual unablated
tumor.
CDAssessment of Safety and Therapeutic Efficacy
Three abdominal radiologists retrospectively reviewed
the CT scans to evaluate the complications and therapeutic
efficacy. The radiologists arrived at a consensus interpreta-
tion of the imaging findings. On follow-up imaging, the
presence of gallbladder wall thickening and abnormal fluid
collection around the gallbladder was evaluated. CT scans
were performed immediately for the evaluation of
gallbladder wall thickening. A total of 34 patients including
six patients who had gallbladder wall edema related to
cirrhosis were evaluated for gallbladder wall thickening.
Thickening of the gallbladder wall was defined as a
thickness greater than 2 mm (13). In cases of gallbladder
wall edema related to cirrhosis, we evaluated whether
mucosal enhancement was present in the wall. Therapeutic
efficacy was assessed by evaluating patients for the
presence of a residual unablated tumor, primary technique
effectiveness and local tumor progression. A residual
unablated tumor was defined as the presence of any
remaining enhancing foci in the ablation zone as depicted
on either contrast-enhanced sonography or early follow-up
CT immediately or at one month after the procedure (18,
19). The primary technique effectiveness rate was defined
as the percentage of tumors that were completely ablated
after the initial procedure, as evidenced on one-month
follow-up CT (19). Local tumor progression was defined as
newly appearing enhancing tumors at or contiguous to the
ablation zone as depicted on follow-up CT after one month
(19). The definitions used for major and minor complica-
tions followed Society of Interventional Radiology
recommendations (19). Patient medical records were
reviewed to evaluate symptoms during and after ablation.
In all patients, whether pain was experienced during or
after the procedures was recorded in the medical records,
including the radiological records. In addition, we
evaluated if pain was tolerated without the administration
of analgesics or was severe and required the administration
of analgesics.
Statistical Analysis
Associations between gallbladder wall thickening and
other variables including tumor location, post-procedural
pain and electrode direction were evaluated using the x
2
test or Fisher’s exact test. The univariate association
between variables (for the direction of electrode insertion,
type of electrode, tumor size, tumor location and lobar
location) and the presence of a residual tumor or local
tumor progression was assessed by the use of Fisher’s exact
test or the x
2 test for trend. P values of less than 0.05 were
considered statistically significant. Data analyses were
performed using SPSS for Windows (version 12.0; SPSS.
Chicago, IL).
Kim et al.
370 Korean J Radiol 10(4), Jul/Aug 2009
Fig. 3. Imaging findings for 66-year-old woman with hepatocellular carcinoma who had gallbladder wall thickening after radiofrequency
ablation are presented. Electrode was inserted into tumor perpendicular to gallbladder wall. 
A. Arterial phase CT scan shows 1.6-cm hepatocellular carcinoma (arrow) adjacent to gallbladder in liver segment V. In addition,
gallstone (double arrows) is noted. 
B. Contrast-enhanced CT scan obtained immediately after radiofrequency ablation shows low-attenuation ablation zone (arrow) larger
than tumor. Also, note mild wall thickening of gallbladder adjacent to ablation zone (double arrows). 
C. Contrast-enhanced CT scan obtained one month after radiofrequency ablation shows disappearance of gallbladder wall thickening.
ABCRESULTS
Safety
There were no treatment-related deaths in the patient
population. In addition, there were no major complications
such as cholecystitis or gallbladder perforation. Three
minor complications (3 of 46, 7%) were noted: one case of
vasovagal syncope and two cases of bilomas. In the patient
where vasovagal syncope occurred, a single ablation was
continued with the use of a lower power setting (5-25 W)
for 15 minutes after recovery from syncope. However, in
this patient, the presence of a residual unablated tumor
was demonstrated on a contrast-enhanced CT scan
obtained immediately after RF ablation (Fig. 2). Two
patients with bilomas showed no progression as seen on
follow-up CT and did not require any treatment.
During the procedure, eight patients (8 of 46, 17%)
complained of severe pain and pain was controlled with an
additional 50 mg IV of pethidine HCl. After the ablation,
severe abdominal pain that required the administration of
analgesics was noted in five patients (5 of 46, 11%). Eight
patients (8 of 46, 17%) presented with low-grade fever
(range, 37.2-38.0 � C; mean, 37.5 � C) after the procedure
that resolved spontaneously after one to two days. Nausea
occurred in three patients (3 of 46, 7%). Right side pleural
effusion occurred in one patient as seen on an immediate
follow-up CT scan and pleural effusion was improved as
demonstrated on one-month follow-up CT.
Focal wall thickening of the gallbladder adjacent to the
RF ablation zone was noted in 14 cases (14 of 34, 41%) as
seen on the immediate follow-up CT. The mean wall
thickness of the gallbladder in the 14 cases was 2.7 mm
(range, 2.0-4.0 mm). Minimal wall thickening of the
gallbladder (2.0-3.0 mm, n = 9) was seen as focal wall
enhancement adjacent to the RF ablation zone. A more
thickened wall (> 3.0 mm, n = 5) was seen as a hypodense
outer layer, a similar appearance to subserosal edema.
Three of six patients who had gallbladder wall edema
related to liver cirrhosis prior to RF ablation had mild
mucosal enhancement. Gallbladder wall thickening was
noted in eight (8 of 14, 57%) of the 14 HCCs that abutted
the gallbladder and in six cases (6 of 20, 30%) among the
20 HCCs that did not abut the gallbladder; this difference
was not statistically significant (p = 0.2). Seven (7 of 14,
50%) of 14 patients with gallbladder wall thickening
complained of upper abdominal pain and 13 patients (13
of 20, 65%) without gallbladder wall thickening
complained of pain. Differences in post-procedural pain
according to the presence or absence of gallbladder wall
thickening were not statistically significant (p = 0.5). The
proportion of gallbladder wall thickening in patients who
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Fig. 4. Imaging findings for 57-year-old man with hepatocellular carcinoma are presented. Electrode was inserted into tumor parallel to
gallbladder wall. 
A. Arterial phase CT scan shows 2.4-cm hepatocellular carcinoma (arrow) abutting gallbladder in liver segment V. 
B. Immediate follow-up CT image after radiofrequency ablation show low-attenuation ablation zone (arrow) and mild focal wall thickening
of gallbladder (double arrows). 
C. Contrast-enhanced CT scan obtained one month after radiofrequency ablation shows disappearance of gallbladder wall thickening.
ABCunderwent RF ablation with parallel direction procedures
(11 of 27, 41%) were similar to the proportion of wall
thickening in patients who underwent RF ablation with
perpendicular direction procedures (3 of 7, 43%); there
was no statistical significance according to the electrode
direction (p = 1.0). In all cases, subsequent follow-up CT
demonstrated the disappearance of gallbladder wall
thickening (Figs. 3, 4). In addition, all patients with
gallbladder wall thickening had a normal WBC count (less
than 8,000 cells/mm
3).
Therapeutic Efficacy
Of the 46 tumors, four (4 of 46, 9%) cases had residual
tumors noted on immediate follow-up imaging (CT, n = 2;
contrast-enhanced US, n = 1) and one-month follow-up CT
(n = 1) (Table 3) (Fig. 2). All tumors abutted the gallblad-
der. The mean diameter of index tumors with a residual
tumor was 3.3 cm. The electrode direction to the gallblad-
der wall was perpendicular in three cases and parallel in
one case. The type of electrode used was a single straight
electrode in all cases with a residual tumor. Based on the
Kim et al.
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Fig. 5. Imaging findings for 59-year-old man with local tumor progression after radiofrequency ablation are presented. Electrode was
inserted into tumor parallel to gallbladder wall. 
A. Contrast-enhanced CT scan obtained during arterial phase shows 3.0-cm hepatocellular carcinoma (arrow) adjacent to gallbladder in
liver segment V. 
B. Oblique sonogram obtained during radiofrequency ablation shows hypoechoic mass adjacent to gallbladder. Single ablation with 3-cm
single straight electrode (arrows) was performed for 12 minutes. Also, note 3-cm active tip of electrode between electronic calipers. 
C. Contrast-enhanced CT scan obtained immediately after radiofrequency ablation shows low-attenuation ablation zone with peripheral
hyperemia (arrow). 
D. Contrast-enhanced CT scan obtained three months after radiofrequency ablation shows nodular enhancing lesion (arrow) at infero-
medial aspect of ablation zone that is indicative of local tumor progression.
CDuse of univariate analyses, the direction of electrode
insertion (perpendicular), tumor size ( 3 cm) and tumor
location (a tumor that abutted the gallbladder) were signifi-
cantly associated with the risk of incomplete treatment (p <
0.05) (Table 1). Two residual unablated tumors were
treated again with a second session of RF ablation on the
next day and no residual unablated tumor was seen on
one-month follow-up CT images. The remaining two
tumors were treated with TACE. Thus, the primary
technique effectiveness rate as depicted on one-month
follow-up CT was 96% (44 of 46). 
Of the 44 tumors that were successfully treated with no
evidence of a residual unablated tumor on one-month
follow-up CT, six tumors (6 of 44, 14%) showed local
tumor progression as seen on follow-up CT performed at
three months (n = 1), four months (n = 3), five months (n =
1) and 17 months (n = 1) (Table 4) (Fig. 5). The maximum
diameter of the index tumors ranged from 0.7 cm to 3.6
RFA of Hepatocellular Carcinomas Adjacent to GB with Internally Cooled Electrodes
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Table 3. Characteristics of Residual Unablated Tumors
No. Location Diameter (cm) Electrode Direction Site*: Proximity to GB Additional Treatment
1 S5 3.2 Perpendicular Yes RF ablation
2 S4 1.5 Perpendicular Yes TACE
3 S5 4.3 Parallel No RF ablation
4 S4 4.0 Perpendicular No TACE
Note.─ *Site of residual tumor within ablation zone.
GB = gallbladder, RF = radiofrequency, TACE = transcatheter arterial chemoembolization
Table 4. Characteristics of Local Tumor Progression
No. Interval (month) Location Diameter (cm) Site*: Proximity to GB Additional Treatment
1 03 S5 3.0 Yes TACE
2 04 S5 0.7 No LT
3 04 S4 3.0 No TACE
4 04 S5 2.7 Yes TACE
5 05 S5 3.6 No TACE
6 17 S4 2.7 Yes TACE
Note.─ *Site of local tumor progression within ablation zone.
GB = gallbladder, TACE = transcatheter arterial chemoembolization, LT = liver transplantation
Table 1. Univariate Analysis of Residual Tumors
Variables
Residual Tumor 
PresentNot  Present
P value
Electrode direction  No. (%) No. (%)
Parallel 1 (3) 37 (97) 0.01
Perpendicular 03 (38) 05 (63)
Electrode type
Single straight 04 (10) 37 (90) 1.00
Clustered 0 (0) 005 (100)
Tumor size
3 cm 03 (27) 08 (73) 0.04
< 3 cm 01 (3)0 34 (97)
Tumor location
Abutting GB 04 (19) -17 (81)0 0.04
0.5 cm from GB 0 (0) -15 (100)
0.6-1.0 cm from GB 0 (0) -10 (100)
Lobar location
Right lobe 2 (6) 31 (94) 0.57
Left lobe 02 (15) 11 (85)
Note.─ GB = gallbladder
Table 2. Univariate Analysis of Local Tumor Progression
Variables
Local Tumor Progression
PresentNot  Present
P value
Electrode direction No. (%) No. (%)
Parallel 05 (13) 33 (87) 1.00
Perpendicular 01 (17) 05 (83)
Electrode type
Single straight 06 (15) 33 (85) 1.00
Clustered 0 (0) 005 (100)
Tumor size
3 cm 03 (30) 07 (70) 0.12
< 3 cm 3 (9) 31 (91)
Tumor location
Abutting GB 02 (11) 17 (90) 0.69
0.5 cm from GB 03 (20) 12 (80)
0.6-1.0 cm from GB 01 (10) 09 (90)
Lobar location
Right lobe 04 (12) 29 (88) 0.63
Left lobe 02 (18) 09 (82)
Note.─ GB = gallbladdercm (mean, 2.6 cm) as measured on sonography. The site of
recurrence was the RF ablation zone near the gallbladder
for three tumors and the opposite portions of the ablation
zone away from the gallbladder for three tumors. No
variable was significantly associated with local tumor
progression based on the use of univariate analyses (p >
0.05) (Table 2). Of the six patients with local tumor
progression, five patients were treated with TACE and one
patient underwent liver transplantation. During the study
period, newly developed HCCs at a site remote from the
ablated tumor were noted in 19 of 43 patients (44%).
Twelve patients died during the study period.
DISCUSSION
Although the use of RF ablation has increased, several
technical limitations remain. Among the limitations,
tumors near the hepatic hilum, large vessels, gastrointesti-
nal tract, gallbladder, diaphragm and heart can be difficult
to treat completely (11-14, 18). RF ablation for these
tumors may result in incomplete necrosis of the index
tumor or collateral thermal damage to adjacent organs.
Therefore, special precautions are needed to treat tumors
in these dangerous locations.
Although RF ablation of tumors adjacent to the gallblad-
der is always accompanied by the risk of gallbladder
perforation or acute cholecystitis, recent clinical studies
have shown that this procedure can be safely and
effectively performed (11-14). Chopra et al. (13) first
reported that percutaneous RF ablation was a feasible and
safe procedure to perform for hepatic tumors located
adjacent to the gallbladder. A few subsequent studies have
yielded similar results for the effectiveness and safety of
this procedure (11, 12, 14). However, the studies have
adopted different types of electrodes and techniques;
expandable electrodes were used in two studies (11, 12)
and cool-tip electrodes were used in one study (14). In one
study, an aseptic solution was injected into the gallbladder
fossa (12).
The results of the current study support the findings of
prior reports claiming that RF ablation for hepatic tumors
adjacent to the gallbladder is a safe procedure. We found
neither procedure-related death nor major complications
that required treatment, consistent with previous investiga-
tions (11-14). Three minor complications in our study
were noted. A vasovagal reaction occurred in one patient,
and this eventually led to incomplete treatment. An RF
study of 1,663 hepatic tumors in 1,139 patients performed
in South Korea had two cases of vasovagal reaction (20).
Although it is uncertain as to whether RF ablation for
tumors adjacent to the gallbladder increases the risk for
vasovagal reaction, stimulation of the gallbladder may
cause gallbladder-cardiac syndrome (12). Therefore,
continuous monitoring of vital signs during the procedure
is mandatory.
Although there was no mortality or significant morbidity
in our study, we found that RF ablation for an HCC near
the gallbladder had a definite thermal effect on the
gallbladder wall as seen on immediate follow-up imaging.
Our findings support the results of a previous report (13)
that found focal transient thermal injury of the gallbladder
wall after RF ablation. These results suggest that RF
ablation around the gallbladder causes reversible thermal
injury of the gallbladder wall due to thermal conduction.
However, severe complications such as overt cholecystitis
or perforation were not encountered; these findings may
be explained by the presence of bile in the gallbladder,
which acts as a source of heat convection. In an experi-
mental study using a pig model, thermal injury to the
gallbladder wall after RF ablation has also been
demonstrated (21). In addition, this study showed that RF
ablation of hepatic tumors that abutted the gallbladder
could cause perforation of the gallbladder unless a safe
distance between the electrode and the gallbladder was
obtained. This serious complication would present as a
delayed process (up to seven days). Although perforation
of the gallbladder did not occur in any of the 21 patients
with tumors that abutted the gallbladder included in this
study, we think that any patient undergoing RF ablation
near the gallbladder without a sufficient safety distance
should be observed carefully for at least seven days after
the procedure.
The incidence of gallbladder wall thickening in other
studies [3 of 53 cases, 6% (11); 3 of 49 cases, 6% (12); 6 of
23 sessions, 26% (13)] differed from the present study (14
of 34 cases, 41%). The size of the index tumor, the type of
electrode used and the criteria for gallbladder wall thicken-
ing might be considered as causes of these differences. In
this study, we found the presence of gallbladder wall
thickening after RF ablation was not related to tumor
location, the development of post-procedural pain and
electrode direction. A previous experimental study showed
that full-thickness thermal injury to the gallbladder was
more frequent in cases with the use of parallel direction
procedures (5 of 12, 42%) as compared to cases with the
use of perpendicular direction procedures (2 of 11, 18%)
(21). However, a relatively small number of cases with the
perpendicular direction procedure were included in our
study and RF ablation for a normal pig liver instead of a
tumor model was performed in the previous experimental
study. Therefore, a comparison between these clinical and
experimental studies may be limited.
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study (96%) was comparable to previously reported
studies using multi-tined expandable electrodes [91% (11)
and 92% (12)]. The fact that the index tumor diameter in
our study (mean diameter, 2.3 cm) was smaller than
previously reported may have contributed to the slightly
improved early therapeutic effectiveness in our study. In
this study, the direction of electrode insertion (perpendicu-
lar), tumor size ( 3 cm), and tumor location (tumors that
abutted the gallbladder) were risk factors of early
incomplete treatment. In addition, there were no residual
tumors for relatively large tumors (mean, 3.5 cm; n = 5)
treated with a clustered electrode. Therefore, the precise
selection of patients and the proper choice of electrode
type and direction to treat tumors adjacent to the gallblad-
der are required to prevent incomplete treatment.
In our study using internally cooled electrodes over a six-
year period, the data included a learning curve for the
preference of the parallel direction as compared to the
perpendicular orientation (38 versus eight). However, we
have recently developed a strategy for the use of the
parallel direction with internally cooled electrodes and the
perpendicular direction with multi-tined electrodes to
avoid the potential risk of wall penetration by a needle
electrode (11). Incomplete ablation was more frequent for
the use of the perpendicular direction in the current study.
We think that two possibilities may explain this finding.
First, the tip of the straight type electrode might be slightly
pulled back due to patient respiration during the ablation.
Second, the electrode might be inserted incompletely in
cases using the perpendicular direction, due to the risk of
gallbladder injury. However, a further study is necessary
to confirm these possibilities.
In several investigations for ablation of hepatic tumors
adjacent to extrahepatic organs, the reported rates of local
tumor progression have varied and have ranged from 2%
to 15% (11-14, 18). Our results for local tumor progres-
sion (14%) were comparable to results of a prior study
using multi-tined expandable electrodes for 53 tumors near
the gallbladder (15%) (11). The difference between this
study and other previous studies (11, 12) is that the differ-
ent types of electrodes were used for RF ablation.
Although the primary technique effectiveness rates for
these two devices showed similar results, we think that the
two devices have relative strengths and weaknesses. An
expandable electrode may be more suited for ablation of
round masses located near the gallbladder because the
shape of the zones of necrosis created with this device
tends to be spherical (16). This device may also have an
advantage in the prevention of tip movement caused by
patient respiration during the ablation procedure.
However, as the use of an expandable electrode is usually
applicable when the electrode can be inserted perpendicu-
larly to the long axis of the gallbladder, a cool-tip electrode
may have advantages over the use of an expandable
electrode for the ablation of small-sized tumors that abut
the gallbladder. In such a situation, these small tumors can
be ablated with the cool-tip electrode inserted parallel to
the long axis of the gallbladder and positioned off center in
the tumor.
This study has the following limitations. First, the study
design was retrospective for evaluation of the use of the
single RF electrode system. There was no standard
protocol (including electrode direction) specific for an HCC
near the gallbladder. Second, we used imaging and clinical
symptoms as indicators of thermal injury of the gallblad-
der. Third, there might be measurement errors for the
distance between the tumor and the gallbladder wall, as
only transverse CT scans were used in this study. Other
limitations were that the follow-up periods of the patients
were relatively short and the length of follow-up varied.
In conclusion, we have successfully treated 45 patients
with 46 HCCs that abutted the gallbladder using an
internal cooled RF electrode system. Gallbladder wall
thickening was frequently seen, but the wall thickening
completely disappeared as seen on subsequent follow-up
CT imaging. The therapeutic efficacy of the study was
comparable to previous studies (11-13). The direction of
electrode insertion (perpendicular), tumor size ( 3 cm)
and tumor location (a tumor that abutted the gallbladder)
were associated with an increased risk of early incomplete
treatment. Therefore, RF ablation of an HCC adjacent to
the gallbladder can be performed safely and effectively
with proper selection of patients and electrode direction.
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